3rd Quarter - Report

HAGGERTY POLICY SOLUTIONS for CALIFORNIA LIFE SCIENCES

Firm
Client
Income
$25,000
Expenses
—

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill. HR 4421/HR 4420 and S. 2333.

LobbyistCovered position, as disclosed
JEANNE HAGGERTY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 127 (118th), S. 2333 (118th), S. 1339 (118th), H.R. 4421 (118th), H.R. 4420 (118th), H.R. 830 (118th)

Medicare/Medicaid MMM

Implementation of the Inflation Reduction Act (IRA) including Medicare Price Negotiation Program policies, including provisions in President Biden's FY 24 Budget Proposal to expand upon the scope of the Program, the biosimilars marketplace, small molecule penalty and the small company exemption. Medicare and Medicaid changes in PBM legislation including Senate MEPA draft, HR 23561 PATIENT Act. CMS's proposed rule for Transitional Coverage of Emerging Technologies (TCET) - lobbied Congress to urge CMS to release the rule and lobbied in support for related legislation, the Ensuring Patient Access to Critical Breakthrough Products Act of 2023, H.R. 1691. Medicare and Medicaid interactions in efforts to reform Pharmacy Benefit Manager (PBM) practices.

LobbyistCovered position, as disclosed
JEANNE HAGGERTY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1691 (118th), H.R. 23561 (118th)

Taxation/Internal Revenue Code TAX

Lobbied in support of H.R. 2673, the American Innovation and R&D Competitiveness Act, and S. 866, the American Innovation and Jobs Act, to restore full deductibility of R&D spending.

LobbyistCovered position, as disclosed
JEANNE HAGGERTY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 866 (118th), H.R. 2673 (118th)

Trade (domestic/foreign) TRD

Lobbied to discuss with Congress the U.S. Trade Representative (USTR) delay on the decision to expand a World Trade Organization intellectual property waiver for COVID-19 vaccines to include COVID diagnostics and therapeutics and how the waiver should not be agreed to. Including potential amendments to the FY24 NDAA reauthorization bill.

LobbyistCovered position, as disclosed
JEANNE HAGGERTY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Banking BAN

Silicon Valley Bank collapse - Congressional oversight and potential action on policy issues surrounding the collapse.

LobbyistCovered position, as disclosed
JEANNE HAGGERTY —

Contacted: HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.